Recently Viewed
Clear All$42.97
$0.00 (0.00%)As on 21-Jun-2024 19:00EDT
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,615 Mln
Revenue (TTM)
$629 Mln
Net Profit (TTM)
$54 Mln
ROE
0 %
ROCE
3.1 %
P/E Ratio
30
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
9.5
Div. Yield
0 %
Debt to Equity
--
Book Value
$47.7
EPS
$1.4
Face value
--
Shares outstanding
37,584,600
CFO
$2,434.92 Mln
EBITDA
$3,954.08 Mln
Net Profit
$2,262.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Taro Pharmaceutical - ADR
| 2.8 | 1.3 | 1.5 | 4.9 | -16.2 | -13.1 | -8.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Taro Pharmaceutical - ADR
| 43.9 | -42.0 | -31.7 | -16.5 | 3.9 | -19.1 | -0.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also... develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited. Read more
CEO & Director
Mr. Uday V. Baldota
VP, CFO & Chief Accounting Officer
Mr. William J. Coote
Headquarters
Haifa
Website
The share price of Taro Pharmaceutical Industries Ltd - ADR is $42.97 (NYSE) as of 21-Jun-2024 19:00 EDT. Taro Pharmaceutical Industries Ltd - ADR has given a return of -16.22% in the last 3 years.
The P/E ratio of Taro Pharmaceutical Industries Ltd - ADR is 30.05 times as on 10-Jul-2024.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
29.54
|
0.89
|
|
2023
|
35.92
|
0.53
|
|
2022
|
27.91
|
0.95
|
|
2021
|
-7.01
|
1.65
|
|
2020
|
9.59
|
1.11
|
The 52-week high and low of Taro Pharmaceutical Industries Ltd - ADR are Rs -- and Rs -- as of 04-Apr-2026.
Taro Pharmaceutical Industries Ltd - ADR has a market capitalisation of $ 1,615 Mln as on 10-Jul-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Taro Pharmaceutical Industries Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.